Immunocore
IMCR
47 hedge funds and large institutions have $617M invested in Immunocore in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 5 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
10% more capital invested
Capital invested by funds: $561M → $617M (+$56.2M)
4% more funds holding
Funds holding: 45 → 47 (+2)
4.08% more ownership
Funds ownership: 34.69% → 38.78% (+4.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$32M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.7M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$16.7M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$8.04M |
| 5 |
First Manhattan
New York
|
+$6.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$14.1M |
| 2 |
BlackRock
New York
|
-$8.52M |
| 3 |
TCM
Tybourne Capital Management
Hong Kong
|
-$5.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$971K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$652K |
IMCR Hedge Fund Activity: Q3 2021 in Review
47 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q3 2021, worth a combined $617M — up 10% from $561M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMCR positions and 5 closed out — a net gain of 2 holders — while 15 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $32M. The largest seller was Deerfield Management, exiting entirely with an estimated $14.1M sold.
- 47 institutional investors held Immunocore (IMCR) as of Q3 2021, up from 45 in Q2 2021.
- Funds reported $617M of Immunocore stock for Q3 2021, up 10% quarter-over-quarter.
- 7 funds opened new Immunocore positions in Q3 2021 and 5 closed out, a net change of +2 holders.
- The largest Immunocore buyer in Q3 2021 was Fidelity Investments, an estimated $32M added.
- The largest Immunocore seller in Q3 2021 was Deerfield Management, an estimated $14.1M sold.
Based on aggregated 13F filings for Q3 2021.